On September 17, 2024, Nomic Bio announced its closing of a $42-million Series B financing round. This round was led by a U.S.-based life-sciences-focused investor and also saw participation from Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures and SR One. Through this funding, the company will increase the expansion of its commercial operations and product offerings.
Nomic Bio is a bioengineering company that focuses on making protein profiling more accessible.
Osler, Hoskin & Harcourt LLP advised with a team consisting of Ryan Unruch, Mihnea Porime, Nik Popovski and Sydney van Vliet (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Associate, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
